Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–280 of 280 matching trials from the live ClinicalTrials.gov search.
Conditions
Obesity and Hypogonadism
Interventions
Testosterone, Lifestyle Therapy, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
65 Years to 85 Years · Male only
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Houston, Texas
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Darolutamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 2 Interventional Results available

Testosterone and Long Pulse Stimulation After SCI

NCT03345576
Conditions
Spinal Cord Injury
Interventions
Testosterone and LPWS, Testosterone and standard NMES
Device · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Obesity; Endocrine, Hormone Disturbance
Interventions
Not listed
Lead sponsor
Precision Analytical, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
144,561 participants
Timeline
2019 – 2023
U.S. locations
1
States / cities
McMinnville, Oregon
Conditions
Multiple Sclerosis, Erectile Dysfunction, Testosterone Deficiency
Interventions
XYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector
Drug
Lead sponsor
Tulane University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New Orleans, Louisiana
Conditions
Prostate Cancer
Interventions
GTx-758 125 mg, GTx-758 250 mg
Drug
Lead sponsor
GTx
Industry
Eligibility
18 Years and older · Male only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
26
States / cities
Burbank, California • Los Angeles, California • San Bernardino, California + 21 more
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Impact of Progestin-only Contraception on Bleeding Patterns in Individuals Initiating GATT

NCT06230770
Conditions
Gender, Contraception
Interventions
Bleeding data
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 50 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Diego, California
Conditions
Klinefelter Syndrome, XXY Syndrome
Interventions
Testosterone gel 1%, Placebo gel
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
8 Years to 18 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Hypogonadism
Interventions
dutasteride, placebo
Drug
Lead sponsor
The Miriam Hospital
Other
Eligibility
40 Years to 85 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Completed Not applicable Interventional Accepts healthy volunteers Results available

Multi-ingredient Supplement for Strength and Power

NCT01971723
Conditions
Supplement
Interventions
T+ Supplement, Placebo
Other
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Tallahassee, Florida
Completed Phase 2 Interventional Results available

Effects of DHEA in Pulmonary Hypertension

NCT03648385
Conditions
Pulmonary Arterial Hypertension
Interventions
DHEA tablet, Placebo
Drug · Other
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Vulvodynia, Vestibulodynia, Vulvar Diseases, Vulvar Vestibulitis, Vulvar Pain
Interventions
BioNourish, a component of the Flourish HEC kit, Control - no intervention
Device · Other
Lead sponsor
Vaginal Biome Science
Other
Eligibility
18 Years to 52 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Virginia Beach, Virginia
Conditions
Men With Low Testosterone Levels
Interventions
Testosterone Enanthate, Placebo
Drug · Other
Lead sponsor
Leonard S. Marks, M.D.
Other
Eligibility
50 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
1
States / cities
Culver City, California
Completed Phase 3 Interventional Results available

A Study of Degarelix in Patients With Prostate Cancer

NCT00928434
Conditions
Prostate Cancer
Interventions
Degarelix, Leuprolide
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
59
States / cities
Alexander City, Alabama • Homewood, Alabama • Anaheim, California + 54 more
Conditions
Klinefelter Syndrome
Interventions
testosterone cypionate 200mg/ml
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
42 Days to 108 Days · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Secondary Hypogonadism
Interventions
Androxal, AndroGel, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 68 Years · Male only
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
18
States / cities
Birmingham, Alabama • Huntsville, Alabama • Carmichael, California + 14 more